Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H, Tavernier J, Fiers W
Imperial Cancer Research Fund Laboratories, London.
Lancet. 1987 Nov 28;2(8570):1229-32. doi: 10.1016/s0140-6736(87)91850-2.
Labile tumour-necrosis-factor-like (TNF) activity was detected by means of an enzyme-linked immunosorbent assay in 50% of 226 freshly obtained serum samples from cancer patients with active disease. In contrast, only 3% of 32 samples from normal subjects and 18% of 39 samples from cancer patients with no clinically evident disease were positive for this factor, with low levels of activity. Greater proportions of serum samples from patients with ovarian or oat-cell carcinoma were positive (69% and 63%) than those from patients with lymphoma (26%). RNA preparations from peripheral-blood mononuclear cells and solid tumours were probed with TNF complementary DNA; evidence of TNF messenger RNA was found in 8 of 11 samples of peripheral-blood mononuclear cells from cancer patients, but only 1 of 8 normal subjects, and in 2 of 6 colorectal tumours. As yet the inducing stimulus and the clinical significance of TNF production in cancer are not understood.
通过酶联免疫吸附测定法在226份来自患有活动性疾病的癌症患者的新鲜血清样本中，有50%检测到不稳定的肿瘤坏死因子样（TNF）活性。相比之下，32份来自正常受试者的样本中只有3%，39份来自无临床明显疾病的癌症患者的样本中只有18%呈该因子阳性，且活性水平较低。卵巢癌或燕麦细胞癌患者血清样本呈阳性的比例（分别为69%和63%）高于淋巴瘤患者（26%）。用TNF互补DNA对外周血单核细胞和实体瘤的RNA制剂进行检测；在11份来自癌症患者的外周血单核细胞样本中有8份发现了TNF信使RNA的证据，但8名正常受试者中只有1份，6份结肠直肠肿瘤中有2份发现了该证据。目前尚不清楚癌症中TNF产生的诱导刺激因素及其临床意义。
